Nicholas Hall's Competitive Intelligence & Market Analysis (CIMA) division is producing a regular news update on the Rx-to-OTC Switch environment – specifically customised to Sanofi internal requirements

Headlines

1

HRA PHARMA LAUNCH ITS ACTUAL USE TRIAL IN USA FOR PROGESTIN-ONLY (NORGESTEL) CONTRACEPTIVE |

USA: September 2019 saw HRA Pharma begin recruiting for a phase 3 clinical trial, designed to assess whether consumers select and use norgestrel 0.075mg (a progestin-only pill for contraception) in a manner consistent with the OTC package direction in an OTC-like setting...

read more >>

2

LAS VEGAS CES 2020 – DIGITAL HEALTH INNOVATIONS |

USA: The gigantic consumer technology show that is CES 2020 took place at Las Vegas in January, (attended by around 170,000 people) displaying technology blurring boundaries between new frontiers in technological advances (AI, robotics) and health & wellness...

read more >>

3

PFIZER TO MARKET VIAGRA THROUGH ROMAN’S TELEHEALTH – DEDICATED DIGITAL HEALTH COMPANY FOR POTENTIALLY SENSITIVE CONDITIONS |

USA: Under a new deal Pfizer’s generic subsidiary, Greenstone, will provide generic Viagra to Roman patients following a telehealth consultation...

read more >>

Focus Areas

1.

Extensive coverage of the World’s innovation, scientific and regulatory environment

Priority 1:

  • Men's health (ED, BPH)
  • Cough
  • Cold
  • Flu
  • Allergy

Priority 2:

  • Digestive Health
  • Sleep
  • Pain (incl. Migraine)

Priority 3:

  • Oral contraception
  • Diabetes
  • Obesity
  • Mental health
  • Heart health (cholesterol, blood pressure, cardiovascular disease)

2.

Areas of switch regulations / environments being monitored

Environment

  • Rx-to-OTC switch regulatory process
  • Health authority goals
  • Government policies
  • KOL and advocacy related activities
  • Clinical research or trial results which could imact efficiacy or safety of existing or future switches

Switch activity

[All switch activity in focus markets across all OTC categories]

  • Any approvals from Health Authorities
  • ... or positive recomendations from switch committee for a switch in one of the focus countries
  • Switch related advisory committee in US
  • Any identified switch related clinical trial inititaion (i.e. from clinicaltrial.gov)
  • Any reverse switch

3.

Adjacencies

[Switch related Digital add-on]

  • Digital medicine
  • Digital therapeutics
  • Use of innovation technology which may enable switch

4.

Focus Markets

  • Japan
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • ISA
  • China
  • Russia
  • Brazil

5.

Commentary highlighting possible impact on Sanofi portfolio